Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders

We report on long-term treatment (13-62 months) with cyclosporin A (CBA) in eight patients with autoimmune haematological disorders, resistant to all usual therapies. Three patients had an autoimmune haemolytic anaemia (AHA); four an idiopathic thrombocytopenic purpura (ITP), and one an Evans syndrome. All patients were responsive: six achieved complete remission and two partial remission. The side-effects were moderate and transient, The majority of surviving patients remain dependent on continued drug administration. The CBA appears to be recommendable as a salvage treatment in life-threatening, resistant autoimmune haematological diseases.